Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population

Head and Neck

Volumn 30, Issue 2, 2008, Pages 178-186

  Epstein, Joshua D ^a   Knight, Tara K ^a   Epstein, Joel B ^b   Bride, Mark A ^c   Nichol, Michael B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Zila Pharmaceuticals Incorporated   (United States)

Author keywords

Carcinoma; Cost and cost analysis; Medicaid; Oral neoplasms; Squamous cell; Utilization

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE FACILITY; HUMAN; HYPOPHARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NASOPHARYNX CANCER; OROPHARYNX CANCER; PHARYNX CANCER; PRIORITY JOURNAL; WALDEYER RING;

ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CARCINOMA, SQUAMOUS CELL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICAID; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PHARYNGEAL NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 39149117396     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20670     Document Type: Article

References (28)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007. Available from URL: http://www.cancer.org/downloads/STT/ CAFF2007PWSecured.pdf [Accessed January 22, 2007].
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press; 2004. Available from URL: http://www-dep.iarc.fr/ [Accessed January 22, 2007].
3. Modi BJ, Knab B, Feldman LE, et al. Review of current treatment practices for carcinoma of the head and neck. Expert Opin Pharmacother 2005;6:1143-1155.
4. Duncan GG, Epstein JB, Tu B, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 2005;27:421-428.
5. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.
6. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
7. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
8. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
9. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
10. Zavras A, Andreopoulos N, Katsikeris N, Zavras D, Cartsos V, Vamvakidis A. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2002;2:12-20.
11. Van Agthoven M, van Ineveld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001;37:2204-2211.
12. Funk GF, Hoffman HT, Karnell LH, et al. Cost-identification analysis in oral cavity cancer management. Otolaryngol Head Neck Surg 1998;118:211-220.
13. Barker GJ, Epstein JB, Williams KB, Gorsky M, Raber-Durlacher JE. Current practice and knowledge of oral care for cancer patients: a survey of supportive health care providers. Support Care Cancer 2005;13:32-41.
14. Epstein JB, Parker IR, Epstein MS, Stevenson-Moore P. Cancer-related oral health care services and resources: a survey of oral and dental care in Canadian cancer centers. J Can Dent Assoc 2004;70:302-304.
15. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539.
16. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100:1995-2003.
17. Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer 2004;12:219-226.
18. Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 2006;106:329-336.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine: the report of the panel on cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
20. Nichol MB, Shi S, Knight TK, Wallace DJ, Weisman MH. Eligibility, utilization, and costs in a California Medicaid lupus population. Arthritis Rheum 2004;51: 996-1003.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
23. Norman GR, Steiner DL. Biostatistics: The bare essentials, 2nd ed. Hamilton: BC Decker; 2000.
24. de Cassia Braga Ribeiro K, Kowalski LP, Latorre Mdo R. Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer. Arch Otolaryngol Head Heck Surg 2003;129:219-228.
25. Centers for Disease Control and Prevention. Tobacco use - United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999;48:986-993.
26. Rubin JH. Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a bio-historical perspective with updates. Carcinogenesis 2001;22:1903-1930.
27. Hunt S, Maerki S, Tompkins R. Comparing CPT code payments for Medi-Cal and other California payers. Price waterhouse-Coopers. Oakland: Medi-Cal Policy Institute; June 2001. Available from URL:http://www.chcf.org/topics/medi-cal/ index.cfm?subtopic=CL271 [Accessed March 16, 2006].
28. Ries LAG, Eisner MP, Kosary CL, et al.SEER Cancer statistics review, 1975-2002. Bethesda, MD: National Cancer Institute; 2005. Available from URL: http://seer.cancer.gov/csr/1975_2002/ or http://seer.cancer.gov/statfacts/html/ oralcav.html [Accessed March 16, 2006].